P-glycoprotein is positively correlated with p53 in human oral pre- malignant and malignant lesions and is associated with poor prognosis

International Journal of Cancer

Volumn 84, Issue 1, 1999, Pages 80-85

  Ralhan, Ranju ^a   Swain, Rajeeb K ^a   Agarwal, Sandhya ^a   Kaur, Jasbir ^a   Nath, Neera ^a   Sarkar, Gautam ^a   Mathur, Meera ^a   Shukla, Nootan K ^b  

^a ALL INDIA INSTITUTE OF MEDICAL SCIENCES   (India)

^b INSTITUTE ROTARY CANCER HOSPITAL   (India)

Author keywords

[No Author keywords available]

Indexed keywords

BETEL EXTRACT; GLYCOPROTEIN P; PROTEIN P53;

ADULT; ARTICLE; CANCER RESISTANCE; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; GENE MUTATION; HUMAN; HUMAN TISSUE; MALE; MOUTH CARCINOMA; MULTIDRUG RESISTANCE; PRECANCER; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; SQUAMOUS CELL CARCINOMA; TOBACCO; TUMOR SUPPRESSOR GENE;

FEMALE; FLOW CYTOMETRY; FOLLOW-UP STUDIES; HUMANS; IMMUNOHISTOCHEMISTRY; INDIA; MALE; MIDDLE AGED; MOUTH NEOPLASMS; P-GLYCOPROTEIN; PRECANCEROUS CONDITIONS; PROGNOSIS; SMOKING; SURVIVAL ANALYSIS; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0032940138     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0215(19990219)84:1<80::AID-IJC15>3.0.CO;2-G     Document Type: Article

References (21)

1. AGARWAL, S., MATHUR, M., SKIVASTAVA, A. and RALHAN, R., MDM2/p53 coexpression in oral pre-malignant and malignant lesions: potential prognostic implications. Europ. J. Cancer B: Oral Oncol. (1998). (In press).
2. BECK, W.T. and 28 OTHERS. Methods to detect P-glycoprotein-associated multidrug resistance in patients tumours: consensus recommendations. Cancer Res., 56, 3010-3020 (1996).
3. DAFTARY, D.K., MURTI, P.R., BHOUSLE, R.R., GUPTA, P.C., MEHRA, F.S. and PINDHORG, J.J., Risk factors and risk markers for oral cancer in high risk areas of the world. In: N.W. Johnson (ed.), Oral cancer: the detection of patients and lesions at risk, pp. 29-63, Cambridge University Press, Cambridge (1991).
4. GREENBLATT, M.S., BENNETT, W.P., HOLLSTEIN, M. and HARRIS, C.C., Mutations in the p53 tumour-suppressor gene: clues to cancer etiology and molecular pathogenesis. Cancer Res., 54, 4855-4878 (1994).
5. HEINZEL, P.A., BALARAM, P. and BERNARD, H.U., Mutations and polymorphisms in the p53, p21 and p16 genes in oral carcinomas of Indian betel quid chewers. Int. J. Cancer, 68, 420-423 (1997).
6. HERMANEK, P. and SOBIN, L.H. (eds.), UICC: TNM classification of malignant tumours (4th ed.), Springer, Berlin (1987).
7. JAIN, V., DAS, S.N., LUTHRA, K., SHUKLA, N.K. and RALHAN, R., Differential expression of multidrug resistance gene product, P-glycoprotein, in normal, dysplastic and malignant oral mucosa in India. Int. J. Cancer, 74, 128-133 (1997).
8. KAUR, J., SKIVASTAVA, A. and RALHAN, R., Over-expression of p53 protein in betel and tobacco related human oral dysplasia and squamous cell carcinoma in India. Int. J. Cancer, 58, 340-345 (1994).
9. KAUR, J., SRIVASTAVA, A. and RALHAN, R., Prognostic significance of p53 protein over-expression in betel and tobacco related oral oncogenesis. Int. J. Cancer, 79, 370-375 (1998a).
10. KAUR, J., SRIVASTAVA, A. and RALHAN, R., Expression of 70kDa heat shock protein in oral lesions: marker of biological stress or pathogenicity. Europ. J. Cancer B: Oral Oncol. (1998b). (In press).
11. LINN, S.C., HONKOOP, A.H., HOEKMAN, K., VALK, P.V.D., PINEDO, H.M. and GIACCONE, G., p53 and P-glycoprotein are often co-expressed and are associated with poor prognosis in breast cancer. Brit. J. Cancer, 74, 63-68 (1996).
12. LOWE, S.W., BODIS, S., MCCLATCHEY, A., REMINGTON, L., RULEY, H.E., FISHER, D.E., HOUSMAN, D. and JACKS, T., p53 status and the efficacy of cancer therapy in vivo Science, 266, 807-810 (1994).
13. LOWE, S.W., RULEY, H.E., JACKS, T. and HOUSMAN, D.E., p53 dependent apoptosis modulates the cytotoxicity of anti-cancer agents. Cell, 74, 957-967 (1993).
14. MUNIRAJAN, A.K., TUTSUMI-ISHII, Y., HOHANPRASAD, B.K.C., HIRANO, Y., MUNAKATA, N., SHANMUGAN, G. and TSUCHIDA, N., p53 gene mutations in oral carcinomas from India. Int. J. Cancer, 36, 297-300 (1996)
15. NGUYEN, K.T., LIU, B., UEDA, K., GOTTESMAN, M.M., PASTAN, I. and CHIN, K.V., Transactivation of the human multidrug resistance (MDRI) gene promoter by p53 mutants. Oncol. Res., 6, 71-77 (1994).
16. OKA, M. and 13 OTHERS, P-Glycoprotein is positively correlated with p53 protein accumulation in human colorectal cancers. Jpn. J. Cancer Res., 88, 738-742 (1997).
17. PEREGO, P., GIAROLA, M., RIGHETTI, S.C., SUPINO, R., CASERINI, C., DELIA, D., PIEROTTI, M.A., MIYASHITA, REED, J.C. and ZUNINO, F., Association between cisplatin resistance and mutation of p53 gene and reduced bax expression in ovarian carcinoma cell systems. Cancer Res., 56, 556-562 (1996).
18. PINEPO, H.M. and GIACCONE, G., P-glycoprotein - a marker of cancer cell behavior. N. Engl. J. Med., 333, 1417-1419 (1995).
19. RALHAN, R., NARAYAN, M., SALOTRA, P., SHUKLA, N.K. and CHAUHAN, S.S., Evaluation of P-glycoprotein expression in human oral oncogenesis: correlation with clinicopathological features. Int. J. Cancer, 72, 728-734 (1997).
20. RAYBAUD-DIOGÈNE, H., TETU, B., MORENCY, R., FORTIN, A. and MONTEIL, R.A., p53 over-expression in head and neck squamous cell carcinoma: review of the literature. Europ. J. Cancer B: Oral Oncol., 32B, 143-149 (1996).
21. THOTTASSERY, J.V., ZAMMETTI, G.P., ARIMORI, K., SCHUETZ, E.G. and SCHUETZ, J.D., p53 dependent regulation of MDRI gene expression causes selective resistance to chemotherapeutic agents. Proc. nat. Acad. Sci. (Wash.), 94, 11037-11042 (1997).